Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Bearish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #13 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 5 Apr 2024 | NEHAL VORA | Employee / designated person | Pledge | 0 | ₹1.59 Cr |
| 4 Apr 2024 | SIVANANDAM K | Other | Pledge | 0 | ₹18.80 L |
| 2 Apr 2024 | Akhilesh Nand | Employee / designated person | Sell | 0 | ₹0 |
| 2 Apr 2024 | KIRAN KUMAR GANDHIRAJAN | Employee / designated person | Sell | 0 | ₹0 |
| 19 Mar 2024 | SHASHI KANT TIWARI | Employee / designated person | Buy | 0 | ₹0 |
| 5 Mar 2024 | MANEESH H GHILDYAL | Employee / designated person | Sell | 0 | ₹0 |
| 5 Mar 2024 | MANEESH H GHILDYAL | Employee / designated person | Sell | 0 | ₹0 |
| 5 Mar 2024 | MANEESH H GHILDYAL | Employee / designated person | Sell | 0 | ₹0 |
| 29 Feb 2024 | MANEESH H GHILDYAL | Employee / designated person | Sell | 0 | ₹0 |
| 29 Feb 2024 | MANEESH H GHILDYAL | Employee / designated person | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 9 Sep 2026 | NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | EDELWEISS MUTUAL FUND | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | SOCIETE GENERALE | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | BAJAJ LIFE INSURANCE LIMITED | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | ACTIV PINE LLP | Block | Sell | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | CITIGROUP GLOBAL MARKETS SINGAPORE PTE LIMITED | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | BNP PARIBAS ARBITRAGE | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | WHITEOAK CAPITAL MUTUAL FUND | Block | Buy | 650,002 | 385.0000 | BSE |
| 9 Sep 2026 | ADITYA BIRLA SUN LIFE MUTUAL FUND | Block | Buy | 1,277,000 | 385.0000 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 3 Jul 2026 | Dividend - Re 0.50 Per Share | 0.5000 | 3 Jul 2026 |
| 4 Jul 2025 | Dividend - Rs 0.50 Per Share | 0.5000 | 4 Jul 2025 |
| 5 Jul 2024 | Dividend - Re 0.50 Per Share | 0.5000 | 5 Jul 2024 |
| 7 Jul 2023 | Dividend - Rs 1.50 Per Share | 1.5000 | 7 Jul 2023 |
| 30 Jun 2022 | Dividend - Rs 0.50 Per Share | 0.5000 | 1 Jul 2022 |
| 18 Jul 2019 | Dividend - Rs 0.50 Per Share | 0.5000 | 19 Jul 2019 |
| 19 Jul 2018 | Dividend- Re 1 Per Share | 1.0000 | 20 Jul 2018 |
| 20 Jul 2017 | Annual General Meeting/Dividend - Re 1/- Per Share | 1.0000 | — |
| 17 Mar 2016 | Interim Dividend - Rs 5/- Per Share (Purpose Revised) | 5.0000 | 19 Mar 2016 |
| 9 Apr 2015 | Interim Dividend Rs 5/- Per Share | 5.0000 | 10 Apr 2015 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 12 Jun 2019 | BONUS | Bonus 1:1 |
| 15 Jun 2017 | BONUS | Bonus 2:1 |
| 11 Sep 2008 | BONUS | Bonus 1:1 |
| 22 Jun 2016 | OTHER | Annual General Meeting |
| 16 Jul 2015 | OTHER | Annual General Meeting |
| 8 Jul 2009 | AGM | Agm/Div-Rs.3/- Per Share Bc Start Date Revised |
| 3 Jul 2008 | OTHER | Fin Div-60% + Spl Div-40% |
| 29 Jun 2006 | AGM | Agm/Fin Div-Rs2.50 Per Sh |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 5 Aug 2026 | Financial Results | Yes |
| 7 May 2026 | Fund Raising | — |
| 7 May 2026 | Financial Results/Dividend | Yes |
| 12 Feb 2026 | Financial Results | Yes |
| 6 Dec 2025 | Fund Raising | — |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 1 Oct 2026 | Company Update | Biocon Ltd - 532523 - Grant Of Employee Stock Options Under Biocon Unity Long Term Incentive Plan 2026 Read With The Notified Plans Thereunder |
| 1 Oct 2026 | Options to purchase securities | Biocon Limited has informed the Exchange about Grant of Employee Stock Options under Biocon Unity Long Term Incentive Plan 2026 read with the Notified Plans thereunder |
| 30 Sep 2026 | Trading Window | Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 30 Sep 2026 | Insider Trading / SAST | Biocon Ltd - 532523 - Closure of Trading Window |
| 25 Sep 2026 | Updates | Biocon Limited has informed the Exchange regarding 'Company Statement'. |
| 25 Sep 2026 | Company Update | Biocon Ltd - 532523 - Company Secretary |
| 21 Sep 2026 | Press Release | Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach". |
| 21 Sep 2026 | Company Update | Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| 9 Sep 2026 | Company Update | Biocon Ltd - 532523 - Communication Regarding Remittance Of Final Dividend For The FY 2025-26 |
| 9 Sep 2026 | General Updates | Biocon Limited has informed the Exchange about Communication regarding remittance of final dividend for the FY 2025-26 |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Single-stock futures and a real listed options chain available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 200, NIFTY 200, NIFTY 500, NIFTY 500, NIFTY MIDCAP 100, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 150, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
